title: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.
authors.affiliation: Celgene Corporation, Warren, New Jersey 07059, USA.
authors.forename: G W
authors.initials: GW
authors.lastname: Muller
authors.forename: L G
authors.initials: LG
authors.lastname: Corral
authors.forename: M G
authors.initials: MG
authors.lastname: Shire
authors.forename: H
authors.initials: H
authors.lastname: Wang
authors.forename: A
authors.initials: A
authors.lastname: Moreira
authors.forename: G
authors.initials: G
authors.lastname: Kaplan
authors.forename: D I
authors.initials: DI
authors.lastname: Stirling
mesh_terms: D006801:Humans; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015394:Molecular Structure; D010797:Phthalimides / Q000138:chemical synthesis / Q000494:pharmacology; D011744:Pyrimidinones / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis*
chemical_list: D008070:Lipopolysaccharides; D010797:Phthalimides; D011744:Pyrimidinones; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide